glp 1 agonist meds New GLP-1 Guidelines for Type 2 Diabetes in 2025 Semaglutide vs. Other GLP-1 Receptor

The trial found that after 5 years, Wegovy significantly reduced the risk of death from heart disease by 15% and reduced the risk of cardiovascular events including nonfatal heart attacks and strokes by 20%, compared to an inactive placebo

52 These results, in part, supported the development of orforglipron as an orally delivered GLP-1RA in clinical testing

Figure 4

The proposed clinical trial endpoints are the resolution of steatohepatitis without worsening or liver fibrosis and/or improvement in liver fibrosis one stage or greater without worsening of steatohepatitis

They may cause nutrition deficiencies and hormone imbalances